Cara Therapeutics, Inc. (NASDAQ:CARA) will hold its 3Q20 earnings conference call with the financial community on 9th November 2020 at 4:30 PM Eastern Time.
The conference call will be webcast live on Internet at www.caratherapeutics.com
Earnings Expectation
Cara Therapeutics, Inc. a clinical-stage biopharmaceutical company, is reporting third quarter earnings results on Monday 9th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.6 per share from $ 4.77 million in revenue. For the full year, analysts predict revenues of $ 22.36 million, while looking forward to loss of $ 2.35 per share.
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the bodys peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease (CKD) associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from chronic kidney disease-associated pruritus.
